| PTLE 0.282 51.53% | SOXS 3.65 11.56% | MSPR 0.664 27.57% | SCNX 0.8182 15.35% | NVDA 198.69 -3.96% | SQQQ 13.79 6.16% | ORIS 0.1603 -0.12% | BYND 1.33 -4.32% | PFE 24.3 -1.46% | HTZ 6.73 36.23% | PLTR 190.74 -7.94% | TSLL 20.34 -10.16% | ETHA 24.28 -10.37% | ASST 1.25 -1.57% | IBIT 57.18 -5.53% | GRAB 5.785 -4.70% | INTC 37.03 -6.25% | PLUG 2.52 -8.36% | ONDS 5.96 -3.09% | OPEN 6.92 -8.83% | CHR 0.136 8.11% | FGL 0.5165 26.94% | DNN 2.74 -6.00% | TSLA 444.26 -5.15% | WTO 0.0497 -6.23% | CAPT 0.6615 31.77% | NFE 1.35 14.41% | SOXL 42.8 -11.90% | BITF 3.84 -6.57% | ETHD 5.26 20.92% | T 24.44 -0.37% | EPWK 0.0748 3.60% | F 12.79 -1.69% | SPY 675.24 -1.19% | SOFI 29.37 -4.11% | KVUE 15.97 -1.05% | ACHR 9.56 -8.25% | CIFR 22.51 -1.10% | QQQ 619.25 -2.03% | HIMS 42.79 -3.60% | GPUS 0.3494 -7.03% | TQQQ 111.08 -6.12% | LQD 110.68 0.14% | BTBT 3.18 -7.02% | AAL 12.65 -5.17% | TZA 8.21 5.26% | BURU 0.29 -7.91% | NCLH 18.79 -15.28% | RGTI 35.18 -10.07% | BTG 4 -5.77%

Waters Corporation (NYSE: WAT) Surpasses Earnings Estimates in Q2 2025

Waters Corporation (NYSE:WAT), a prominent player in the medical instruments industry, known for its innovative solutions in liquid chromatography and mass spectrometry, recently reported its second-quarter 2025 earnings. The company showcased a strong performance with earnings per share (EPS) of $2.95, surpassing the estimated $2.93. This marks a consistent trend of outperforming consensus EPS estimates over the past four quarters.

Despite generating revenue of $771.3 million, slightly below the estimated $775.7 million, Waters demonstrated a significant year-over-year increase from $708.53 million. The company's revenue exceeded the Zacks Consensus Estimate by 3.63%, highlighting its robust growth trajectory. Instrument sales, particularly in liquid chromatography and mass spectrometry, contributed to this growth, driven by strong replacement trends among pharmaceutical and CDMO customers.

Waters' financial metrics provide further insights into its market valuation. With a price-to-earnings (P/E) ratio of approximately 26.10, the market values the company's earnings favorably. The price-to-sales ratio of about 5.76 and an enterprise value to sales ratio of 6.14 reflect the market's positive perception of Waters' revenue generation capabilities. Additionally, the enterprise value to operating cash flow ratio of 24.15 suggests a strong market valuation of the company's cash flow.

The company's strategic initiatives and product adoption have been pivotal in its performance. Dr. Udit Batra, President & CEO, attributes the success to effective execution of commercial growth initiatives. Waters has raised its full-year 2025 constant currency sales growth guidance to between 5.5% and 7.5%, and its non-GAAP EPS guidance to between $12.95 and $13.05, indicating confidence in continued growth.

Waters maintains a healthy financial position with a debt-to-equity ratio of approximately 0.78, indicating a balanced approach to financing its assets. The current ratio of about 1.81 further underscores the company's ability to meet short-term liabilities with its short-term assets, ensuring financial stability.

Published on: August 4, 2025